11 Jan 2019 Research

Myelofibrosis: Finding new ways to treat patients

Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.

Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.

Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.

The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.

Related posts

UK’s top chefs unite at gastronomic spectacular to raise funds for life-saving leukaemia research

5 July 2023

UK’s top chefs unite at gastronomic spectacular to raise funds for life-saving leukaemia research

Twenty of the most accomplished and innovative chefs from the UK food scene will gather at The Dorchester on Monday 18th September 2023 for ‘Who’s Cooking Dinner?’, a one-of-a-kind night…

Leukaemia UK unveils an exciting new brand 

10 August 2022

Leukaemia UK unveils an exciting new brand 

Leukaemia UK has today revealed a bold new look and feel that embodies the charity’s ambitious new strategy and our desire to be a greater force for change.  Bringing together…

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

25 November 2025

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…

The National Cancer Plan: what does it mean for people with leukaemia?

11 February 2026

The National Cancer Plan: what does it mean for people with leukaemia?

The Government’s new National Cancer Plan for England, which launched on World Cancer Day 2026, marks the most significant progress in policy for leukaemia and other blood cancers in more…